ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0486

Baseline Characteristics of Non-Dialysis CKD Patients with and Without Anemia: A Report from the Retrospective Cohort from DISCOVER CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Wittbrodt, Eric T., AstraZeneca, Gaithersburg, Maryland, United States
  • Carrero, Juan Jesus, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • James, Glen, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, United Kingdom
  • Fishbane, Steven, Northwell Health, Manhasset, New York, United States
  • Kumar, Supriya R., AstraZeneca, Gaithersburg, Maryland, United States
  • Pecoits-Filho, Roberto, Pontificia Universidade Catolica do Parana, Curitiba, PR, Brazil
  • Garcia Sanchez, Juan Jose, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, United Kingdom
  • Pollock, Carol A., University of Sydney, Sydney, New South Wales, Australia
  • Sloand, James A., AstraZeneca, Gaithersburg, Maryland, United States
  • Hedman, Katarina, AstraZeneca, Gothenburg, Sweden
  • Wheeler, David C., University College London, London, London, United Kingdom

Anemia is a frequent complication of chronic kidney disease (CKD), associated with adverse clinical outcomes and reduced quality of life. This analysis describes baseline characteristics of non-dialysis dependent (NDD) CKD patients with and without anemia in DISCOVER CKD.


The DISCOVER CKD retrospective cohort of patients in this analysis were extracted from the TriNetX health research network, Japan Medical Data Vision (JMDV) and integrated Limited Claims and EHR (LCED) databases. Patients were aged >18 years with 2 estimated glomerular filtration rate (eGFR) measures <60 mL/min/1.73m2 >90 days apart between January 2008 and March 2020. The index date was the first Hb measure (regardless of value) or an anemia therapy (iron, ESA or blood transfusion) prescription after the 2nd eGFR measure. Exclusion criteria included: <1-year registration/medical history prior to index, active bleeding, a Hb value (only) within 30 days from transfusion or bleeding and no Hb measure within a year after CKD diagnosis. Anemia was defined as <12 g/dL [females], <13 g/dL [males] per WHO criteria. Baseline characteristics were summarized and stratified by presence of anemia.


Preliminarily, of 709183 CKD patients meeting our I/E criteria, 67% were not anemic at baseline. In patients with anemia (33%): 191451 (81%) had a baseline Hb of 10-12(female)/10-13(male)g/dL, 36889 (16%) 8-10g/dL and 6906 (3%) <8g/dL. Compared to patients without anemia: patients with anemia were older, more likely to be female, to have more advanced CKD, and more likely to have comorbidities.


In routine clinical care, the presence and severity of anemia increases as CKD advances and is associated with a higher comorbidity burden.